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Abstract
Objectives: The aim of this analysis was to examine prognostic features and outcomes in patients
undergoing resection for intrahepatic cholangiocarcinoma (ICC).
Methods: A retrospective chart review was performed in all patients who underwent R0 or R1 resection
for primary ICC between 1995 and 2011. Clinical data were abstracted and statistical analyses were
conducted in the standard fashion.
Results: A total of 82 patients underwent curative hepatectomy for primary ICC; 51 patients in this
cohort developed recurrence. The median follow-up of survivors was 27 months (range: 1–116 months).
Recurrences were intrahepatic (65%), associated with multiple tumours (54%) and occurred during the
first 2 years after hepatectomy (86%). The main factor associated with recurrence after resection was the
presence of satellite lesions. Overall 5-year disease-free survival after primary resection was 16%.
Factors associated with poor survival were transfusion and perineural invasion. Treatment of recurrence
was undertaken in 89% of patients and repeat surgical resection was performed in 15 patients. The 3-year
survival rate after recurrence was 25%. Prolonged survival after recurrence was associated with a solitary
tumour recurrence.
Conclusions: Despite curative resection of ICC, recurrence can be expected to occur in 79% of patients
at 5 years. Predictors of survival and recurrence after resection vary in the literature. In patients with
recurrence, selection of the optimal treatment remains challenging.
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Introduction
Intrahepatic cholangiocarcinoma (ICC) is the second most
common primary hepatic malignancy after hepatocellular carci-
noma and accounts for 5–10% of all cholangiocarcinomas.1,2 In
recent years, the increasing incidence reported in Western coun-
tries is at least in part related to growing recognition of this entity;
in the past ICCs were often thought to be metastatic tumours
from an unknown primary site.1–5 Hepatic resection is considered
the first-line treatment in patients with ICC who have no evidence
of distant metastases.6 In this setting, resection provides 5-year
survival of 22–40%.6,7 However, 70% of patients present with
advanced disease at diagnosis and have a median survival time
of 9 months.6 Recurrence after resection remains high, with rates
reported to lie between 44% and 70% at 5 years.8 Treatment
of recurrent ICC remains challenging, with options including
repeat resection, ablation, embolization, radiation and systemic
chemotherapy.
Because of the rarity and low resectability rate of ICC, prog-
nostic factors subsequent to resection have not been clearly estab-
lished. In addition, options for the management of recurrence are
not well described. The primary aim of this study was to define
outcomes and identify prognostic features in patients undergoing
curative treatment for ICC. In addition, the study aimed to deter-
mine risk factors and outcomes in patients with recurrent disease.
This study was presented as a poster at the SSO Conference, 6–9 March 2014,
Maryland.
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Materials and methods
Institutional review board approval was obtained and prospec-
tively collected data from the Mount Sinai Medical Center were
retrospectively reviewed. All consecutive patients with pathologi-
cally proven ICC who underwent hepatic resection with curative
intent between January 1995 and January 2011 were included. The
surgery was performed at a tertiary centre by two experienced
hepatobiliary surgeons. The endpoint of the data collection was
April 2014. Patients with hilar or distal cholangiocarcinoma, gall-
bladder cancer and hepatocellular carcinoma were excluded, as
were patients with ICC who underwent liver transplantation.
Patients who underwent R2 resection were also excluded. The
primary endpoint analysed was overall survival from the date of
primary resection. The secondary endpoint was time to progres-
sion from date of recurrence.
Preoperative variables examined included age, gender, underly-
ing liver disease, extent of initial resection, interval from resection
to recurrence, and Child–Pugh class. Pathological data on both
the initial and recurrent tumours were examined, including data
on size, number of tumours, presence of satellite nodules, grade
of differentiation, presence and degree of vascular invasion,
perineural invasion, and lymph node metastases. Satellite nodules
were defined as tumour nodules of ≤2 cm in diameter located
≤2 cm from the primary tumour.
All patients underwent preoperative contrast-enhanced com-
puted tomography (CT) or magnetic resonance imaging (MRI) of
the chest and abdomen. Biopsy was not typically performed prior
to surgery. Consideration for resection required the patient to be
non-cirrhotic or to be cirrhotic with Child–Pugh class A status
with no evidence of portal hypertension (platelet count
>100 000/μL and absence of varices and splenomegaly on
endoscopy/imaging).
Laparoscopy was performed routinely before laparotomy.Resec-
tion was undertaken only in the absence of peritoneal spread and
contralateral liver metastasis. Limited lymph node involvement in
the porta hepatis did not preclude resection, but nodal metastases
extending to the coeliac or para-aortic region were considered to
represent metastatic disease and a reason not to proceed.
Intraoperative ultrasound was employed prior to and during resec-
tion. Systematic portal lymphadenectomy was performed rou-
tinely. Patients with lymph node involvement or positive surgical
margins typically received adjuvant chemotherapy with or without
external beam radiation. Routine common bile duct resection was
not performed. Portal vein resection and reconstruction were per-
formed in patients with macroscopic invasion.
After hepatectomy, patients were followed with serial tumour
marker [carbohydrate antigen (CA) 19-9] levels and contrast-
enhanced imaging studies of the chest and abdomen. Surveillance
was carried out every 3 months for the first year, every 4 months
for the second year, and biannually thereafter. Diagnosis of recur-
rence was established by radiographic means, rising CA 19-9, or
by tissue biopsy in select circumstances in patients with atypical
imaging characteristics.
Repeat resection was considered in patients with a single site of
recurrence, either intra- or extrahepatic. Patients with limited
Figure 1 Rates of overall recurrence in patients with intrahepatic cholangiocarcinoma (ICC) after primary hepatectomy (n = 81)
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intrahepatic recurrence who were not eligible for resection were
treated with radiofrequency ablation if feasible (one to three
tumours of <4 cm in size). Patients with multinodular isolated
hepatic recurrence exceeding these limits were treated with
transarterial chemoembolization (TACE) or radioembolization.
Systemic chemotherapy employing a variety of regimens was
offered to patients with unresectable systemic disease, as well as to
patients with intrahepatic recurrence concomitant with
locoregional treatments. A multimodal approach to treatment was
standard practice for patients presenting with recurrent ICC.
Categorical variables were expressed as percentages and com-
pared using the chi-squared test. Continuous variables were
expressed as the median (range) and tested with the Mann–
Whitney U-test. Survival was calculated in months from the time
of primary resection until the last clinical or telephone encounter,
or death. Recurrence and time to recurrence were included to
Table 1 Characteristics of patients with intrahepatic cholangiocarcinoma (ICC) at presentation (n = 82)
Clinical, operative and pathological variables At presentation P-value
Group 1
No recurrence
n = 31 (38%)
Group 2
Recurrence
n = 51 (62%)
Age, years, median (range) 63 (44–77) 60 (31–86) 0.419
Male gender, n (%) 20 (64%) 20 (39%) 0.026
Ethnicity, n (%)
White 16 (52%) 39 (77%) 0.037
Asian 9 (31%) 5 (10%)
Other 5 (17%) 5 (10%)
Symptoms at presentation, n (%) 13 (42%) 26 (51%) 0.426
Cirrhosis, n (%) 4 (13%) 3 (6%) 0.261
Extent of resection, n (%)
Right lobectomy 12 (36%) 13 (26%)
Right trisectionectomy 2 (6%) 2 (6%)
Left lobectomy 7 (21%) 16 (33%)
Left trisectionectomy 0 8 (16%)
Segmentectomy 8 (24%) 6 (12%)
Other 4 (12%) 5 (10%)
Pringle manoeuvre, n (%) 7 (87%) 41 (80%) 0.434
Transfusion, n (%) 10 (32%) 15 (29%) 0.786
Solitary tumour nodule, n (%) 29 (93%) 44 (86%) 0.307
Tumour size, cm, median (range) 7 (3–21) 8 (3–17) 0.405
Histological differentiation, n (%) 0.857
Good 1 (4%) 2 (4%)
Moderate 12 (46%) 25 (52%)
Poor 13 (50%) 21 (44%)
Vascular invasion, n (%) 0.247
None 18 (58%) 20 (39%)
Microinvasion 12 (39%) 28 (55%)
Macroinvasion 1 (3%) 3 (6%)
Perineural invasion, n (%) 7 (23%) 15 (29%) 0.498
Lymph node involvement, n (%) 6 (19%) 15 (29%) 0.312
Satellite nodules, n (%) 3 (10%) 17 (33%) 0.019
Surgical margin, mm
Median (range) 7 (0–35) 6 (0–30) 0.502
Positive (R1), n (%) 1 (3%) 14 (28%) 0.007
Adjuvant chemotherapy ± radiotherapy 1 (3%) 22 (43%) <0.001
Follow-up, months, median (range) 23 (1–116) 29 (2–100) 0.238
HPB 2015, 17, 344–351
346 HPB
© 2014 International Hepato-Pancreato-Biliary Association
Table 2 Predictors of recurrence after primary resection (n = 81) in univariate and multivariate analyses
Variable n (number of events) Time to recurrence, months,
median (95% CI)
P-value
Age
≤60 years 33 (23) 15 (7–23) 0.267
>60 years 48 (28) 22 (12–32)
Gender
Male 39 (20) 27 (8–46) 0.165
Female 42 (31) 17 (14–21)
Underlying liver disease
None 56 (37) 18 (15–21) 0.270
Present 25 (14) 27 (0–57)
Number of tumours
Single 9 (7) 16 (14–19) 0.111
Multiple 72 (44) 19 (13–25)
Positive margin
Yes 19 (14) 23 (14–32) 0.573
No 60 (36) 18 (11–24)
Adjuvant treatment 0.003
Yes 23 (22) 15 (5–25)
No 58 (29) 24 (7–40)
Vascular invasion
Yes 44 (31) 16 (9–24) 0.011
No 37 (20) 34 (5–64)
Satellites
Yes 20 (17) 9 (5–13) <0.001a
No 60 (34) 27 (10–43)
Perineural invasion
Yes 21 (15) 9 (3–16) 0.020
No 60 (36) 22 (15–28)
Lymph node involvement
Yes 21 (15) 11 (3–19) 0.018
No 60 (36) 23 (7–39)
Symptoms
Yes 39 (26) 18 (13–22) 0.515
No 42 (25) 22 (15–29)
Differentiation
Good 3 (2) 9 (–) 0.529
Moderate 37 (25) 22 (15–29)
Poor 33 (21) 18 (1–34)
Size
≤5 cm 24 (14) 34 (5–63) 0.149
>5 cm 56 (37) 18 (11–25)
Cirrhosis
Yes 7 (3) 23 (–) 0.284
No 72 (47) 18 (12–24)
Transfusion requirement
No 56 (36) 22 (11–32) 0.665
Yes 25 (15) 18 (14–21)
Extent of vascular invasion
No 37 (20) 34 (5–64) 0.031
Microvascular 40 (28) 16 (9–23)
Macrovascular 4 (3) 8 (3–14)
aSignificant on multivariate analysis: presence of satellites (P = 0.012, odds ratio 2.532, 95% CI 1–5).
95% CI, 95% confidence interval.
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evaluate their impact on survival. Patient survival and recurrence
rates were calculated using the Kaplan–Meier method and com-
pared using the log-rank test. Perioperative deaths (at <30 days)
were excluded from the outcome analysis. Variables found to be
significantly associated with the endpoint on univariate analysis
(P < 0.2) were entered into a Cox proportional hazards model to
identify independent predictors. A P-value of <0.05 was consid-
ered significant on multivariate analysis. Analysis was carried out
using IBM spss Statistics for Windows Version 20.0 (IBM Corp.,
Armonk, NY, USA).
Results
During the study period, 86 patients underwent hepatic resection
for ICC. Four of these patients had an R2 resection and were
excluded. In the remaining 82 patients, an R0 resection was
achieved in 67 (82%) and an R1 resection was performed in 15
(18%). Extrahepatic bile duct resection was performed in 14
(17%) patients in whom the intrahepatic tumour mass extended
to the biliary confluence. Portal vein resection and reconstruction
were performed in four (5%) patients with macroscopic invasion.
By the end of the study period, 49 (60%) patients had died and
51 (62%) had developed recurrence. One (1%) perioperative
death occurred; this patient was excluded from the survival analy-
sis. The median follow-up of survivors was 27 months (range:
1–116 months). The initial clinical, pathologic and operative data
are summarized in Table 1.
The median time from primary resection to recurrence was 18
months [95% confidence interval (CI) 12–25 months] and the
median follow-up after recurrence was 16 months (range: 1–91
months). Data on overall recurrence is shown in Fig. 1. Recur-
rences were noted to be intrahepatic (n = 32, 63%), multiple
lesions (n = 27, 53%) and to occur most often during the first 2
years after hepatectomy (n = 42, 82%). Sites of extrahepatic recur-
rence (n = 17) included lymph nodes (n = 7), lung (n = 3), bone (n
= 3), peritoneum (n = 2), brain (n = 1) and ovary (n = 1). Factors
associated with recurrence after primary resection are summa-
rized in Table 2.
Treatment of recurrence was undertaken in 41 (89%) patients
and included surgical resection (n = 15), locoregional therapy (n =
13), systemic therapy alone (n = 13) and supportive care (n = 5).
Surgical resection (n = 15) included repeat liver resection for
localized intrahepatic recurrence (n = 10) or metastasectomy
(ovary, n = 1; brain, n = 1; lung, n = 2; vertebra, n = 1).
The overall survival of patients with recurrent disease is shown
in Fig. 2. Median disease-free survival was 16 months (95% CI
Figure 2 Rates of overall survival in patients with intrahepatic cholangiocarcinoma (ICC) after primary hepatectomy, with recurrent and
non-recurrent disease (P = 0.275) (n = 81)
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Table 3 Predictors of survival after primary resection (n = 81) in univariate and multivariate analyses
Variable n (number of events) Survival, months, median (95% CI) P-value
Age
≤60 years 33 (17) 52 (32–73) 0.330
>60 years 48 (31) 27 (5–50)
Gender 0.586
Male 39 (25) 27 (2–52)
Female 42 (23) 46 (23–70)
Underlying liver disease 0.131
None 56 (37) 31 (19–44)
Present 25 (11) 97 (26–168)
Number of tumours
Single 73 (42) 41 (15–67) 0.153
Multiple 9 (7) 27 (3–51)
Recurrence
Yes 51 (35) 38 (23–54) 0.193
No 30 (13) >median
Positive margin
Yes 19 (11) 38 (6–70) 0.850
No 60 (35) 41 (14–68)
Adjuvant treatment
Yes 23 (15) 31 (16–36) 0.241
No 58 (33) 46 (15–78)
Vascular invasion
Yes 42 (26) 24 (17–30) 0.020
No 38 (22) 57 (19–96)
Satellites
Yes 20 (12) 24 (18–30) 0.028
No 60 (35) 52 (30–74)
Perineural invasion
Yes 21 (15) 20 (12–27) 0.001a
No 60 (33) 55 (35–76)
Lymph node involvement
Yes 21 (11) 26 (14–37) 0.250
No 60 (37) 46 (26–66)
Symptoms
Yes 39 (23) 38 (14–62) 0.769
No 42 (25) 41 (12–71)
Differentiation
Good 3 (1) 22 (–) 0.824
Moderate 37 (21) 41 (29–54)
Poor 33 (19) 55 (32–79)
Size
≤5 cm 24 (14) 57 (9–106) 0.869
>5 cm 56 (33) 39 (20–58)
Cirrhosis
Yes 7 (4) 52 (0–111) 0.851
No 72 (43) 39 (20–58)
Transfusion requirement
No 56 (29) 55 (33–78) 0.014a
Yes 25 (19) 23 (10–36)
Extent of vascular invasion
No 37 (21) 57 (20–95) 0.027
Microvascular 40 (23) 27 (8–46)
Macrovascular 4 (4) 7 (0–26)
aSignificant on multivariate analysis.
Perineural invasion (P = 0.015, odds ratio 2.403, 95% CI 1−5).
Transfusion requirement (P = 0.021, odds ratio 2.134, 95% CI 1–4).
95% CI, 95% confidence interval.
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11–21 months), with 1-, 3- and 5-year disease-free survival rates
of 60%, 24% and 16%, respectively. Predictors of survival after
primary hepatic resection are shown in Table 3. The median sur-
vival after recurrence was 19 months (95% CI 15–23 months) and
1- and 3-year survival rates were 74% and 25%, respectively. Age,
gender, underlying liver disease, site of recurrence, and time to
recurrence (<12 months) were not significant predictors of sur-
vival after recurrence. Prolonged survival after recurrence was
associated with the presence of a solitary tumour recurrence (P =
0.032).
Discussion
The role of hepatectomy in the treatment of ICC is well estab-
lished.3,6,9 However, recurrence is common despite resection of
ICC, as is apparent by the 79% rate of recurrence at 5 years
identified in the current series. This study analysed the outcomes
of 82 consecutive patients with ICC treated with curative resection
at a single Western centre over a 16-year period.
Recurrence in this series occurred most often (86%) during the
first 2 years after hepatectomy, with a median time to recurrence
of 18 months. The liver remnant was the most common site of
recurrence (65%). In this series, predictors of recurrence were
satellite nodules. Endo et al. reported that multiple tumours,
regional nodal involvement and large tumour size represented
independent predictors of poor recurrence-free survival following
resection.6
This study demonstrates a 5-year disease-free survival rate of
16% with a median follow-up of 27 months. Predictors of poor
survival in the present series were transfusion requirements and
perineural invasion. Independent predictors of survival in other
published studies were age <40 years, lymphatic invasion, and
preoperative CA 19-9 levels of >37 ng/dL.3,10–12 Interestingly, the
current series did not demonstrate an association between posi-
tive margins and poor survival. In other series, margins of <1 cm
were associated with decreased survival rates.9 Efforts to achieve
wide surgical margins whenever possible are therefore advocated.
Recurrence rates are high despite attempted curative treatment;
however, approaches to recurrent ICC remain controversial and
challenging. Limited data exist on the treatment of recurrence
after primary resection for ICC.8,9,13–16 Various treatment modali-
ties have been proposed in recent years in patients with recurrent
disease. Locoregional therapies such as radiofrequency ablation
(RFA), TACE and transarterial radioembolization have been
shown to be safe and effective in the treatment of ICC.17–20
Locoregional therapies were offered to 26% of patients in the
present study and achieved a 3-year survival rate of 35% in
patients with unresectable recurrent disease. Elsewhere, the treat-
ment of recurrent cholangiocarcinoma after curative resection
with RFA resulted in a median overall survival of 27.4 months in
a series of 20 patients.18 Sulpice et al. discussed the role of
yttrium-90 radioembolization and demonstrated a significant
survival benefit in the treatment of recurrent ICC.16 Similarly,
Saxena et al.19 reported disease control in 72% of treated patients,
and Whitney et al.21 demonstrated tumour downstaging in a sub-
group of patients treated with yttrium-90. Kiefer et al. reported
local tumour control with the use of TACE in the treatment of
unresectable ICC.22
There are even fewer data on the role of repeat resection in the
management of isolated recurrent disease.9,13,16,23 Recent published
series report the resection of recurrent ICC in 8.5–30% of
patients.8,9,13–16 Repeat resection in the treatment of recurrent ICC
has been demonstrated as an independent predictor of overall
survival in several series. Among the patients with liver-only
recurrence in the present series, 10 had preserved liver function
and isolated disease, and thus were candidates for second hepate-
ctomy. In addition, five patients with isolated extrahepatic disease
were selected for repeat resection. Low statistical power and the
heterogeneity of this group of patients limit the ability to further
evaluate this subgroup.
Conclusions
In summary, despite curative resection of ICC, recurrence can be
expected to occur in 79% of patients at 5 years. Predictors of
survival and recurrence after resection vary in the literature. In
patients with recurrence, selection of the optimal treatment
remains challenging.
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